A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
Recruiting now · Phase 4
Conditions studied: Nasopharyngeal Cancer Recurrent
In brief
This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
Key facts
- Study ID
- NCT06457503
- Run by
- Coherus Oncology, Inc.
- People needed
- 100
- Starts
- 2024-11-01
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2026-07-30
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Princess Margaret Cancer Centre — Toronto, Canada, Canada (enrolling)
- University of California, Irvine — Irvine, California, United States (enrolling)
- University of California, San Francisco — San Francisco, California, United States (enrolling)
- Emory Winship Cancer Institute — Atlanta, Georgia, United States (enrolling)
- Boston Medical Center — Boston, Massachusetts, United States (enrolling)
- University of Michigan — Ann Arbor, Michigan, United States (enrolling)
- Henry Ford Cancer Center — Detroit, Michigan, United States (enrolling)
- University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States (enrolling)
- University of Cincinnati Medical Center — Cincinnati, Ohio, United States (enrolling)
- Cleveland Clinic — Cleveland, Ohio, United States (enrolling)
- Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States (enrolling)
- Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.